| 0.03 -0.004 (-10.98%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.09 | 1-year : | 0.11 |
| Resists | First : | 0.08 | Second : | 0.09 |
| Pivot price | 0.05 |
|||
| Supports | First : | 0.03 | Second : | 0 |
| MAs | MA(5) : | 0.06 |
MA(20) : | 0.04 |
| MA(100) : | 0.16  |
MA(250) : | 0.48 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.7 |
D(3) : | 76.2 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 1.27 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ITRM ] has closed below upper band by 6.1%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Sat, 12 Sep 2026
Iterum Therapeutics plc (ITRM) Free Cash Flow 2024: $26.8M outflow, up 32.0% - Stock Titan
Sat, 29 Aug 2026
Iterum Therapeutics PLC (ITRM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Wed, 01 Apr 2026
Breakeven On The Horizon For Iterum Therapeutics plc (NASDAQ:ITRM) - simplywall.st
Wed, 01 Apr 2026
Iterum Therapeutics plc (NASDAQ:ITRM): Are Analysts Optimistic? - finance.yahoo.com
Tue, 31 Mar 2026
Iterum Therapeutics to be delisted from Nasdaq as winding up process advances - Investing.com
Tue, 31 Mar 2026
Iterum Therapeutics Received Notice of Delisting - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 5.237e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 1,750 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.932e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 982.3 % |
| Return on Equity (ttm) | -53.3 % |
| Qtrly Rev. Growth | 390000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 38538.2 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.59 |
| Dividend | 0 |
| Forward Dividend | 3.07e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|